• Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

Medicines Writeup

Extracts from this document...


Purpose of the Report In Angiomax, the Medicines Company ("Medicines") has developed its first FDA approved drug for commercial sale to patients undergoing angioplasties. Yet this milestone may prove meaningless unless the Company can devise a profitable marketing strategy to launch its product and begin generating revenues. To achieve this goal, Medicines must determine Angiomax's optimal position, target market, pricing, promotion, and distribution strategy. In the long-run, however, even a highly successful launch of Angiomax may not provide enough revenue to cover the company's fixed costs and generate high returns demanded by investors. Indeed, long-term success calls for matching Medicines' strengths and resources with the specific products in its pipelines to ensure sustainable profitability. Recommendations To maximize profitability, we recommend that Medicines adopt the following roll-out strategy: * First target very high risk angioplasties by promoting primarily to research hospitals, and then expand in high-risk angioplasties at the 700 centers responsible for 92% of procedures. * Position Angiomax as a safer and more effective alternative anticoagulant drug to Heparin. * Set a premium price - $350 per dose for Angiomax. * Use push-based selective demand stimulation directed primarily toward doctors. Furthermore, we recommend that Medicines expand its drug discovery pipeline to include other cardiopulmonary drugs to leverage the customer relationships developed in the marketing of Angiomax. Analysis The Benefits of Angiomax Based on the Phase III trial data performed by Biogen, we have calculated the potential benefits Angiomax (Exhibit 1). ...read more.


of Angiomax has been established. Our logic rests on three facts: 1) Targeting the VHR segment first will help hospitals to realize a larger financial benefit 2) Targeting the VHR segment first will also reduce the chance that Angiomax fails to produce the appearance of resultsii due to low base rates of complications; 3) Total marketing costs of this tiered approach may actually be less as success in the VHR market will increases word-of-mouth advertising and thus reduces the need to spend money in the HR market. When approaching the VHR and then the HR segment, we recommend that Medicines position Angiomax as a safer and more effective alternative anticoagulant drug to Heparin for the high-risk and very high-risk Angioplasty patients. Pricing Strategy Compared to Heparin, Angiomax should be positioned as a premium product due to its higher effectiveness, predictability, and safety and more importantly (for hospitals) the extra value created. With the same drug, Medicines can not credibly price discriminate between the VHR and HR segments. Thus we recommend one price be set using the aggregate EVC of both segments. Specifically, Medicine should charge $350 per dose. We arrive at this number by first calculating Angiomax' EVC per dose (see Exhibit 2). However, we do not think that consumers can understand EVC and $457 price might be higher than consumers' inherent willingness to pay. ...read more.


Business Model Consideration Rolling out Angiomax is only the first step in the grand plans of Medicines. However, we find that the Company's long-term strategy questionable. First, the model of acquiring abandoned drugs may reduce development costs, but the lack of synergistic drugs in its pipeline may prevent the Company from fully leveraging its resources. Developing Angiomax shows the skills Medicines has in cardio-drugs and builds relationships with Cardiologists. However, targeting drugs in other fields may dilute Medicines brand while also requiring costly marketing in non-cardio medical fields. A second important constraint in the current business model is the availability of new drugs to acquire. Big pharmaceutical companies will not easily give up a drug to Medicines if they feel the drug may be the next blockbuster. One way to remedy these problems would be to enter into purchase contracts for abandoned drugs where the seller will take on marketing responsibilities. This would allow Medicines to leverage the scale of Companies like Merck to ensure cost efficiencies. If this proves impossible, Medicines should at least increase its efforts in finding additional cardiopulmonary drugs to better build brand and leverage resources. i Note that we consider the market to be "procedures" and thus segment by type of angioplasty. We deal with individual decision-makers such as doctors, pharmacists, etc. later in this report. ii In HR patients, only 7% will actually benefit from receiving Angiomax instead of Heparin, while almost 14% of VHR patients will benefit from receiving Angiomax. ?? ?? ?? ?? ...read more.

The above preview is unformatted text

This student written piece of work is one of many that can be found in our GCSE Marketing and Markets section.

Found what you're looking for?

  • Start learning 29% faster today
  • 150,000+ documents available
  • Just £6.99 a month

Not the one? Search for your essay title...
  • Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

See related essaysSee related essays

Related GCSE Marketing and Markets essays

  1. Strategic Marketing Report - Virgin Trains

    All these once again associated to psychology. 12 Conclusion I feel Virgin Trains has a lot of stay within its market, its current strategy involves nearly no advertising what so ever, which in this susceptible age is not a clever move.

  2. Questionnaire Effectiveness

    the area or elsewhere - the business target market alone could not possibly give effective enough answers to this. The first question was a fact question, i.e. those questioned had to answer it based on fact and not opinion. The first 10 questions in the questionnaire were opinion based and

  1. This report will focus on the adult palliative care provided by SAH proposing a ...

    Gantt Chart Figure 35 - Costs Figure 36 - Limitations and Challenges of the proposed strategy/marketing 1.0 Key terms Key Term Description SAH St Ann's Hospice Hospice A program that provides special care for people who are near the end of life and for their families, either at home, in freestanding facilities, or within hospitals.

  2. AVON Case Analysis

    motivate, and retain the number of active Sales Representatives it needs to sustain significant growth. Avon also has a Representative development program that focuses on the professional training of Representatives, which enables them to provide valuable information on Avon brand products.

  1. Marketing Strategy - Nintendo Gamecube

    Reading product reviews from the Internet, buying game magazines and talking with my friends about it will carry this out. I can then read the theory about marketing and the various aspects on the topic and apply the theory to what I know about the Gamecube and the market that

  2. Design a small scale marketing plan and formal report for a small business.

    Again I will use the market research to decide on my target market because it will tell me about the market I am setting up in. I will also create a name for Jack's business by conducting some market research on initial ideas I have thought of.

  • Over 160,000 pieces
    of student written work
  • Annotated by
    experienced teachers
  • Ideas and feedback to
    improve your own work